Dose discrepancies in the buildup region and their impact on dose calculations for IMRT fields

Dosimetric characterization of foam padding with posterior fields in palliative radiation therapy

Patients undergoing external beam radiation therapy for the palliative treatment of painful bony metastases may have difficulty maintaining a still position on a rigid uncovered couch top, both during CT simulation as well as during patient setup, image guidance, and treatment on the linear accelerator. For these patients, a thin foam pad or mattress is sometimes used to mitigate patient discomfort. It was desired to quantify the effect of the padding in cases in which the patient is to be treated supine with posterior beams when the majority of the beam weighting traverses both the couch and the pad. Ion chamber measurements in-phantom were acquired with 6 MV, 10 MV, and 15 MV photon beams. At depths of maximum dose, the pad resulted in a difference of signal collected ≤1%. At the phantom surface, the pad resulted in an increase in signal ranging from 1% to 6.5% for the measured beams. CT data of the pad, both with and without applied pressure, indicated that the pad had average HU values close to air.

Monte Carlo modelling and validation of the elekta synergy medical linear accelerator equipped with radiosurgical cones

Monte Carlo simulations of medical linear accelerator heads help in visualizing the energy spectrum and angular spread of photons and electrons, energy deposition, and scattering from each of the head components. Hence, the purpose of this study was to validate the Monte Carlo model of the Elekta synergy medical linear accelerator equipped with stereotactic radio surgical connical collimators. For this, the Elekta synergy medical linear accelerator was modelled using the EGSnrc Monte Carlo code. The model results were validated using the measured data. The primary electron beam parameters, beam size, and energy were tuned to match the measured data; a dose profile with a field size of 40 × 40 cm² and percentage depth dose with a field size of 10 × 10 cm² were matched during tuning. The validation of the modelled data with the measurement results was performed using gamma analysis, point dose, and field size comparisons. For small radiation fields, relative output factors were also compared. The gamma analysis revealed good agreement between the Monte Carlo modeling results and the measured data. A gamma pass rate of more than 95% was obtained for field sizes of 40 × 40 cm² to 2 × 2 cm² with gamma criteria of 1% and 1 mm for the dose difference (DD) and distance to agreement (DTA), respectively; this gamma pass rate was more than 98% for the corresponding values of 2% and 2 mm for the DD and DTA, respectively. A gamma pass rate of more than 99% was obtained for a percentage depth dose with 1 mm and 1% criteria. The field size was also in good agreement with the measurement results, and the maximum deviation observed was 1.1%. The stereotactic cone field also passed this analysis with a gamma pass rate of more than 98% for dose profiles and 99% for the percentage depth dose. The small field output factor exhibited a deviation of 4.3%, 3.4%, and 1.9% for field sizes of 5 mm, 7.5 mm, and 10 mm, respectively. Thus, the Monte Carlo model of the Elekta Linear accelerator was successfully validated. The validation of radio surgical cones passed the analysis in terms of the dose profiles and percentage depth dose. The small field relative output factors exhibited deviations of up to 4.3%, and to resolve this, detector-specific and field-specific correction factors must be derived.

Dosimetric study of whole-brain irradiation with high-energy photon beams for dose reduction to the scalp

OBJECTIVE

To evaluate the efficiency of high-energy photons for mitigating alopecia due to whole-brain irradiation (WBRT).

METHODS

Planning CT data from 10 patients who received WBRT were collected. We prepared 4 WBRT plans that used 6 or 15 MV photon beams, with or without use of a field-in-field (FiF) technique, and compared outcomes using a treatment planning system. The primary outcome was dose parameters to the scalp, including the mean dose, maximum dose, and dose received to 50% scalp(D50%). Secondary outcomes were minimum dose to the brain surface.

RESULTS

Using FiF, the mean doses were 24.4-26.0 and 22.4-24.1 Gy, and the maximum doses were 30.5-32.1 and 28.5-30.8 Gy for 6 and 15 MV photon beams, respectively. Without FiF, the mean doses were 24.6-26.9 and 22.6-24.5 Gy, and the maximum doses were 30.8-34.6 and 28.6-32.4 Gy for 6 and 15 MV photon beams. The 15 MV plan resulted in a lower scalp dose for each dose parameter (p < 0.001). Using FiF, the minimum doses to the brain surface for the 6 and 15 MV plans were 28.9 ± 0.440 and 29.0 ± 0.557 Gy, respectively (p = 0.70). Without FiF, the minimum doses to the brain surface for the 6 and 15 MV plans were 28.9 ± 0.456 and 29.0 ± 0.529, respectively (p = 0.66).

CONCLUSION

Compared with the 6 MV plan, the 15 MV plan achieved a lower scalp dose without impairing the brain surface dose.

ADVANCES IN KNOWLEDGE

High-energy photon WBRT may mitigate alopecia of patients who receiving WBRT.

Skin dose in chest wall radiotherapy with bolus: a Monte Carlo study

Monte Carlo simulations are used to investigate skin dose resulting from chest wall radiotherapy with bolus. A simple model of a female thorax is developed, which includes a 2 mm-thick skin layer. Two representative 6 MV source models are considered: a tangents source model consisting of a parallel opposed pair of medial and lateral fields and subfields, and an arc source model. Tissue equivalent (TE) boluses (thicknesses of 3, 5 and 10 mm) and brass mesh bolus are considered. Skin dose distributions depend on incident photon obliquity: for tangents, radiation is incident more obliquely, resulting in longer path lengths through the bolus and higher skin dose compared to the arc source model in most cases. However, for thicker TE boluses, attenuation of oblique photons becomes apparent. Brass bolus and 3 mm TE bolus result in similar mean skin dose. This relatively simple computational model allows for consideration of different bolus thicknesses, materials and usage schedules based on desired skin dose and choice of either tangents or an arc beam technique. For example, using a 5 mm TE bolus every second treatment would result in mean skin doses of 89% and 85% for tangents and the arc source model, respectively. The hot spot metric D[Formula: see text] would be 103% and 99%, respectively.

Dosimetric impact of tracheostomy devices in head and neck cancer patients

INTRODUCTION

The tracheostomy site and adjacent skin is at risk for recurrence in head/neck squamous cell cancer patients. The tracheostomy tube is an in situ device located directly over the tracheostomy site and may have clinical implications on the radiation dose delivered to the peristomal region. This study aimed to investigate this effect by comparing the prescribed treatment planning dose with the actual dose in vivo to the peristomal clinical target region. A retrospective, dosimetric study was performed with approval of the institutional research ethics board.

METHODS

Fifteen patients who had received high-dose radiotherapy to the tracheostomy region with in vivo dose measurements were included. The radiation dose at the skin surface underneath the tracheostomy device was measured using an optically stimulated luminescent dosimeter (OSLD) and was compared with the prescribed dose from the radiation planning system. The effect of the tracheostomy flange and/or soft tissue equivalent bolus on the peristomal dose was calculated.

RESULTS AND DISCUSSION

Patients with tracheostomy equipment in situ were found to have a 3.7% difference between their prescribed and actual dose. With a tissue equivalent bolus there was a 2.0% difference between predicted and actual. The mean prescribed single fraction dose (mean = 191.8 cGy, SD = 40.18) and OSLD measured dose (mean = 194.02 cGy, SD = 44.3) were found to have no significant difference. However, with the flange excluded from the planning simulation (density = air) target skin dose deviated from predicted by an average of 55.3% (range = 12.4-72.9, SD = 22.5) and volume coverage was not achieved.

CONCLUSION

In summary, the tracheostomy flange acts like bolus with a twofold increase in the skin surface dose. Changes in the peristomal apparatus from simulation to treatment needs to be considered to ensure that the simulated dose and coverage is achieved.

Detector response in the buildup region of small MV fields

PURPOSE

The model used to calculate dose distributions in a radiotherapy treatment plan relies on the data entered during beam commissioning. The quality of these data heavily depends on the detector choice made, especially in small fields and in the buildup region. Therefore, it is necessary to identify suitable detectors for measurements in the buildup region of small fields. To aid the understanding of a detector's limitations, several factors that influence the detector signal are to be analyzed, for example, the volume effect due to the detector size, the response to electron contamination, the signal dependence on the polarity used, and the effective point of measurement chosen.

METHODS

We tested the suitability of different small field detectors for measurements of depth dose curves with a special focus on the surface-near area of dose buildup for fields sized between 10 × 10 and 0.6 × 0.6 cm² . Depth dose curves were measured with 14 different detectors including plane-parallel chambers, thimble chambers of different types and sizes, shielded and unshielded diodes as well as a diamond detector. Those curves were compared with depth dose curves acquired on Gafchromic film. Additionally, the magnitude of geometric volume corrections was estimated from film profiles in different depths. Furthermore, a lead foil was inserted into the beam to reduce contaminating electrons and to study the resulting changes of the detector response. The role of the effective point of measurement was investigated by quantifying the changes occurring when shifting depth dose curves. Last, measurements for the small ionization chambers taken at opposing biasing voltages were compared to study polarity effects.

RESULTS

Depth-dependent correction factors for relative depth dose curves with different detectors were derived. Film, the Farmer chamber FC23, a 0.13 cm³ scanning chamber CC13 and a plane-parallel chamber PPC05 agree very well in fields sized 4 × 4 and 10 × 10 cm² . For most detectors and in smaller fields, depth dose curves differ from the film. In general, shielded diodes require larger corrections than unshielded diodes. Neither the geometric volume effect nor the electron contamination can account for the detector differences. The biggest uncertainty arises from the positioning of a detector with respect to the water surface and from the choice of the detector's effective point of measurement. Depth dose curves acquired with small ionization chambers differ by over 15% in the buildup region depending on sign of the biasing voltage used.

CONCLUSIONS

A scanning chamber or a PPC40 chamber is suitable for fields larger than 4 × 4 cm² . Below that field size, the microDiamond or small ionization chambers perform best requiring the smallest corrections at depth as well as in the buildup region. Diode response changes considerably between the different types of detectors. The position of the effective point of measurement has a huge effect on the resulting curves, therefore detector specific rather than general shifts of half the inner radius of cylindrical ionization chambers for the effective point of measurement should be used. For small ionization chambers, averaging between both polarities is necessary for data obtained near the surface.

Effect of VERO pan-tilt motion on the dose distribution

Tumor tracking is an option for intra-fractional motion management in radiotherapy. The VERO gimbal tracking system creates a unique beam geometry and understanding the effect of the gimbal motion in terms of dose distribution is important to assess the dose deviation from the reference conditions. Beam profiles, output factors (OF) and percentage depth doses (PDD) were measured and evaluated to investigate this effect. In order to find regions affected by the pan-tilt motion, synthesized 2D dose distributions were generated. An evaluation of the 2D dose distribution with the reference position was done using dose difference criteria 1%-4%. The OF and point dose at central axis were measured and compared with the reference position. Furthermore, the PDDs were measured using a special monitoring approach to filtering inaccurate points during the acquisition. Beam profiles evaluation showed that the effect of pan-tilt at inline direction was stronger than at the crossline direction. The maximum average deviation of the full width half maximum (FWHM), flatness, symmetry, penumbra left and right were 0.39 ± 0.25 mm, 0.62 ± 0.50%, 0.76 ± 0.59%, 0.22 ± 0.16 mm, and 0.19 ± 0.15 mm respectively. The ÔF and the measured dose average deviation were <0.5%. The mechanical accuracies during the PDD measurements were 0.28 ± 0.09 mm and 0.21 ± 0.09 mm for pan and tilt and pan or tilt position. The PDD average deviations were 0.58 ± 0.26 % and 0.54 ± 0.25 % for pan-or-tilt and pan-and-tilt position respectively. All the results showed that the deviation at pan and tilt position are higher than pan or tilt. The most influences were observed for the penumbra region and the shift of radiation beam path.

A patient immobilization device for prone breast radiotherapy: Dosimetric effects and inclusion in the treatment planning system

PURPOSE

To assess the dosimetric impact of a patient positioning device for prone breast radiotherapy and assess the accuracy of a treatment planning system (TPS) in predicting this impact.

METHODS

Beam attenuation and build-up dose perturbations, quantified by ionization chamber and radiochromic film dosimetry, were evaluated for 3 components of the patient positioning device: the carbon fiber baseplate, the support cushions and the support wedge for the contralateral breast. Dose calculations were performed using the XVMC dose engine implemented in the Monaco TPS. All components were included during planning CT acquisition.

RESULTS

Beam attenuation amounted to 7.57% (6MV) and 5.33% (15MV) for beams obliquely intersecting the couchtop-baseplate combination. Beams traversing large sections of the support wedge were attenuated by 12.28% (6MV) and 9.37% (15MV). For the support cushion foam, beam attenuation remained limited to 0.11% (6MV) and 0.08% (15MV) per centimeter thickness. A substantial loss of dose build-up was detected when irradiating through any of the investigated components. TPS dose calculations accurately predicted beam attenuation by the baseplate and support wedge. A manual density overwrite was needed to model attenuation by the support cushion foam. TPS dose calculations in build-up regions differed considerably from measurements for both open beams and beams traversing the device components.

CONCLUSIONS

Irradiating through the components of the positioning device resulted in a considerable degradation of skin sparing. Inclusion of the device components in the treatment planning CT allowed to accurately model the most important attenuation effect, but failed to accurately predict build-up doses.

Hair-sparing whole brain radiotherapy with volumetric arc therapy in patients treated for brain metastases: dosimetric and clinical results of a phase II trial

Purpose

To report the dosimetric results and impact of volumetric arc therapy (VMAT) on temporary alopecia and hair-loss related quality of life (QOL) in whole brain radiotherapy (WBRT).

Methods

The potential of VMAT-WBRT to reduce the dose to the hair follicles was assessed. A human cadaver was treated with both VMAT-WBRT and conventional opposed field (OF) WBRT, while the subcutaneously absorbed dose was measured by radiochromic films and calculated by the planning system. The impact of these dose reductions on temporary alopecia was examined in a prospective phase II trial, with the mean score of hair loss at 1 month after VMAT-WBRT (EORTC-QOL BN20) as a primary endpoint and delivering a dose of 20 Gy in 5 fractions. An interim analysis was planned after including 10 patients to rule out futility, defined as a mean score of hair loss exceeding 56.7. A secondary endpoint was the global alopecia areata severity score measured with the “Severity of Alopecia Tool” (SALT) with a scale of 0 (no hair loss) to 100 (complete alopecia).

Results

For VMAT-WBRT, the cadaver measurements demonstrated a dose reduction to the hair follicle volume of 20.5% on average and of 41.8% on the frontal-vertex-occipital medial axis as compared to OF-WBRT. In the phase II trial, a total of 10 patients were included before the trial was halted due to futility. The EORTC BN20 hair loss score following WBRT was 95 (SD 12.6). The average median dose to the hair follicle volume was 12.6 Gy (SD 0.9), corresponding to a 37% dose reduction compared to the prescribed dose. This resulted in a mean SALT-score of 75.

Conclusions

Compared to OF-WBRT, VMAT-WBRT substantially reduces hair follicle dose. These dose reductions could not be related to an improved QOL or SALT score.

Evaluation of six TPS algorithms in computing entrance and exit doses

Entrance and exit doses are commonly measured in in vivo dosimetry for comparison with expected values, usually generated by the treatment planning system (TPS), to verify accuracy of treatment delivery. This report aims to evaluate the accuracy of six TPS algorithms in computing entrance and exit doses for a 6 MV beam. The algorithms tested were: pencil beam convolution (Eclipse PBC), analytical anisotropic algorithm (Eclipse AAA), AcurosXB (Eclipse AXB), FFT convolution (XiO Convolution), multigrid superposition (XiO Superposition), and Monte Carlo photon (Monaco MC). Measurements with ionization chamber (IC) and diode detector in water phantoms were used as a reference. Comparisons were done in terms of central axis point dose, 1D relative profiles, and 2D absolute gamma analysis. Entrance doses computed by all TPS algorithms agreed to within 2% of the measured values. Exit doses computed by XiO Convolution, XiO Superposition, Eclipse AXB, and Monaco MC agreed with the IC measured doses to within 2%‐3%. Meanwhile, Eclipse PBC and Eclipse AAA computed exit doses were higher than the IC measured doses by up to 5.3% and 4.8%, respectively. Both algorithms assume that full backscatter exists even at the exit level, leading to an overestimation of exit doses. Despite good agreements at the central axis for Eclipse AXB and Monaco MC, 1D relative comparisons showed profiles mismatched at depths beyond 11.5 cm. Overall, the 2D absolute gamma (3%/3 mm) pass rates were better for Monaco MC, while Eclipse AXB failed mostly at the outer 20% of the field area. The findings of this study serve as a useful baseline for the implementation of entrance and exit in vivo dosimetry in clinical departments utilizing any of these six common TPS algorithms for reference comparison.

PACS numbers: 87.55.‐x, 87.55.D‐, 87.55.N‐, 87.53.Bn

Calculation of organ doses from breast cancer radiotherapy: a Monte Carlo study

The current study aimed to: a) utilize Monte Carlo simulation methods for the assessment of radiation doses imparted to all organs at risk to develop secondary radiation induced cancer, for patients undergoing radiotherapy for breast cancer; and b) evaluate the effect of breast size on dose to organs outside the irradiation field. A simulated linear accelerator model was generated. The in-field accuracy of the simulated photon beam properties was verified against percentage depth dose (PDD) and dose profile measurements on an actual water phantom. Off-axis dose calculations were verified with thermoluminescent dosimetry (TLD) measurements on a humanoid physical phantom. An anthropomorphic mathematical phantom was used to simulate breast cancer radiotherapy with medial and lateral fields. The effect of breast size on the calculated organ dose was investigated. Local differences between measured and calculated PDDs and dose profiles did not exceed 2% for the points at depths beyond the depth of maximum dose and the plateau region of the profile, respectively. For the penumbral regions of the dose profiles, the distance to agreement (DTA) did not exceed 2 mm. The mean difference between calculated out-of-field doses and TLD measurements was 11.4% ± 5.9%. The calculated doses to peripheral organs ranged from 2.32 cGy up to 161.41 cGy depending on breast size and thus the field dimensions applied, as well as the proximity of the organs to the primary beam. An increase to the therapeutic field area by 50% to account for the large breast led to a mean organ dose elevation by up to 85.2% for lateral exposure. The contralateral breast dose ranged between 1.4% and 1.6% of the prescribed dose to the tumor. Breast size affects dose deposition substantially.

Monte Carlo Simulation of Siemens ONCOR Linear Accelerator with BEAMnrc and DOSXYZnrc Code

The Monte Carlo method is the most accurate method for simulation of radiation therapy equipment. The linear accelerators (linac) are currently the most widely used machines in radiation therapy centers. In this work, a Monte Carlo modeling of the Siemens ONCOR linear accelerator in 6 MV and 18 MV beams was performed. The results of simulation were validated by measurements in water by ionization chamber and extended dose range (EDR2) film in solid water. The linac's X-ray particular are so sensitive to the properties of primary electron beam. Square field size of 10 cm × 10 cm produced by the jaws was compared with ionization chamber and film measurements. Head simulation was performed with BEAMnrc and dose calculation with DOSXYZnrc for film measurements and 3ddose file produced by DOSXYZnrc analyzed used homemade MATLAB program. At 6 MV, the agreement between dose calculated by Monte Carlo modeling and direct measurement was obtained to the least restrictive of 1%, even in the build-up region. At 18 MV, the agreement was obtained 1%, except for in the build-up region. In the build-up region, the difference was 1% at 6 MV and 2% at 18 MV. The mean difference between measurements and Monte Carlo simulation is very small in both of ONCOR X-ray energy. The results are highly accurate and can be used for many applications such as patient dose calculation in treatment planning and in studies that model this linac with small field size like intensity-modulated radiation therapy technique.

Verification of calculated skin doses in postmastectomy helical tomotherapy

PURPOSE

To verify the accuracy of calculated skin doses in helical tomotherapy for postmastectomy radiation therapy (PMRT).

METHODS AND MATERIALS

In vivo thermoluminescent dosimeters (TLDs) were used to measure the skin dose at multiple points in each of 14 patients throughout the course of treatment on a TomoTherapy Hi·Art II system, for a total of 420 TLD measurements. Five patients were evaluated near the location of the mastectomy scar, whereas 9 patients were evaluated throughout the treatment volume. The measured dose at each location was compared with calculations from the treatment planning system.

RESULTS

The mean difference and standard error of the mean difference between measurement and calculation for the scar measurements was -1.8% ± 0.2% (standard deviation [SD], 4.3%; range, -11.1% to 10.6%). The mean difference and standard error of the mean difference between measurement and calculation for measurements throughout the treatment volume was -3.0% ± 0.4% (SD, 4.7%; range, -18.4% to 12.6%). The mean difference and standard error of the mean difference between measurement and calculation for all measurements was -2.1% ± 0.2% (standard deviation, 4.5%: range, -18.4% to 12.6%). The mean difference between measured and calculated TLD doses was statistically significant at two standard deviations of the mean, but was not clinically significant (i.e., was <5%). However, 23% of the measured TLD doses differed from the calculated TLD doses by more than 5%.

CONCLUSIONS

The mean of the measured TLD doses agreed with TomoTherapy calculated TLD doses within our clinical criterion of 5%.